

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application Number: **10/572,778**
Applicant: **BERG, Stefan, *et al.***
Filed: **March 21, 2006**
TC/A.U.: **1626**
Examiner: **BIANCHI, Kristin A**

AstraZeneca Docket No. **101192-1P US**
Customer No. **22466**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

The owner, AstraZeneca AB, of 100% of the above-identified application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the full statutory term of prior U.S. Patent 7,399,780, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such periods that any patent so granted on the above-identified application and U.S. Patent 7,399,780 are co-owned. This agreement shall be binding on the grantee, its successors or assigns

Provided: The owner does not disclaim the terminal part of the statutory term of any patent granted on the above-identified application prior to the earlier of (i) the full statutory term of prior U.S. Patent 7,399,780 or (ii) the full statutory term of any patent granted on the above-identified application in the event that prior U.S. Patent 7,399,780 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or is terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a re-examination certificate, is reissued, or is otherwise terminated prior to expiration of its full statutory term.

The undersigned is an attorney of record.

The Terminal Disclaimer fee under 37 C.F.R. § 1.20(d) is to be charged to deposit account No. 260166 referencing Attorney Docket No. 101192-1P US/NS.

Respectfully submitted,

Dated: July 20, 2009

By: / Kenneth F. Mitchell /
Kenneth F. Mitchell, Ph.D., J.D.
Reg. No. 42,007
Telephone: 302/886-7466